The estimated Net Worth of Medical Fund Lp Gullans Ste... is at least $2.93 Milhão dollars as of 5 July 2017. Medical Ste owns over 60,000 units of Aileron Therapeutics Inc stock worth over $2,926,368 and over the last 7 years Medical sold ALRN stock worth over $0.
Medical has made over 1 trades of the Aileron Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Medical bought 60,000 units of ALRN stock worth $900,000 on 5 July 2017.
The largest trade Medical's ever made was buying 60,000 units of Aileron Therapeutics Inc stock on 5 July 2017 worth over $900,000. On average, Medical trades about 60,000 units every 0 days since 2017. As of 5 July 2017 Medical still owns at least 1,016,100 units of Aileron Therapeutics Inc stock.
You can see the complete history of Medical Ste stock trades at the bottom of the page.
Over the last 14 years, insiders at Aileron Therapeutics Inc have traded over $6,473,296 worth of Aileron Therapeutics Inc stock and bought 16,658,005 units worth $51,661,886 . The most active insiders traders include Muneer A Satter, Bioventures Ltd Novartis Ag..., eArmen Shanafelt. On average, Aileron Therapeutics Inc executives and independent directors trade stock every 77 days with the average trade being worth of $908,853. The most recent stock trade was executed by Of Texas/Texas Am Investmen... on 14 June 2024, trading 6,607 units of ALRN stock currently worth $21,539.
aileron is the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases. our lead product candidate, alrn-6924, which is being evaluated in multiple clinical trials, reactivates p53-mediated tumor suppression by targeting both of the primary p53 suppressor proteins mdmx and mdm2. the p53 protein, often referred to as the “guardian of the genome,” is known for its central role in preventing cancer initiation and progression, and its inactivation is essential for the formation of virtually all cancers. we believe that alrn-6924 is the first and only product candidate in clinical development that can inhibit both mdmx and mdm2, which we believe, based on published data and our preliminary clinical results, are equally important in restoring p53 function as the body’s first line of defense against cancer. based on preclinical data and preliminary evidence of safety and anti-tumor activity in our ongoing clinical trials, we believe there may be a sig
Aileron Therapeutics Inc executives and other stock owners filed with the SEC include: